Felip, Enriqueta

Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.

Neal, J. W., Santoro, A., Viteri, S., Ponce Aix, S., Fang, B., Lim, F. L., Gentzler, R. D., Goldschmidt, J. H., Khrizman, P., Massarelli, E., et al. (2022) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 18

A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology

Lazar, V., Zhang, B., Magidi, S., Le Tourneau, C., Raymond, E., Ducreux, M., Bresson, C., Raynaud, J., Wunder, F., Onn, A., et al. (2023) · Therapeutic Advances in Medical Oncology

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies

Cited by 14

MA06.03 Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non-Small Cell Lung Cancer: The Global TRUST-II Study

Liu, G., Yang, N., Choi, C.-M., Ohe, Y., Sugawara, S., Yanagitani, N., De Braud, F., Nieva, J., Nagasaka, M., Zhou, C., et al. (2024) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 4

33P: A multi-country time & motion (T&M) study of subcutaneous (SC) vs intravenous (IV) pembrolizumab (Pembro) plus chemotherapy (Chemo) in metastatic non-small cell lung cancer (mNSCLC)

De Cock, E., Oskar, S., Lourdudoss, C., Eiras, R., Pietanza, C., Arunachalam, A., Alves, G. V., & Felip, E. (2025) · Journal of Thoracic Oncology

Lung Cancer Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 1